Progyny (NASDAQ:PGNY) versus BG Medicine (OTCMKTS:BGMD) Head-To-Head Contrast

BG Medicine (OTCMKTS:BGMD) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares BG Medicine and Progyny”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Progyny	$1.29 billion	1.08	$58.52 million	$0.65	26.11

Progyny has higher revenue and earnings than BG Medicine.

Profitability

This table compares BG Medicine and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Progyny	4.54%	11.37%	7.73%

Analyst Recommendations

This is a summary of current ratings and recommmendations for BG Medicine and Progyny, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Progyny	0	4	9	0	2.69

Progyny has a consensus price target of $27.91, indicating a potential upside of 64.46%. Given Progyny’s stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than BG Medicine.

Insider & Institutional Ownership

94.9% of Progyny shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by insiders. Comparatively, 9.4% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

BG Medicine has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Summary

Progyny beats BG Medicine on 9 of the 10 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.